FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access ...

Within the tumors, the team identified clones, groups of cells with similar genetic makeup. Individual tumors contained ...

According to BCC Research, the global gene synthesis market is projected to grow from $3.4 billion in 2026 to $7.2 billion by ...

A diet rich in vegetables, fruits, whole grains, nuts, olive oil and fish may help protect brain health. According to the ...

Humans and chimpanzees share almost all their genes. Despite this, our brains have developed in different ways. Researchers ...

Researchers have identified seven candidate biomarker genes for Parkinson's disease by combining transcriptomic data analysis, Mendelian randomization, and machine learning, then validating ...

Gene therapy is no longer the future of medicine—it's reality. Treatments that replace, silence or edit genes are already ...

Researchers from Rice and Baylor College of Medicine have secured NIH funding to develop a novel, non-DNA-altering CRISPR ...

Though scientists have made great inroads into understanding human genetics, editing our genes has remained a complex process requiring imprecise, expensive technology, years of expertise and just a ...

The activity of six different genes can help determine survival in patients with acute myeloid leukemia (AML), according to a ...

Some of the leaders of the AI race are calling for a slowdown, for safety's sake. Viewed in economics terms, it's a collective action problem: no one wants to slow down unless everyone does.

Taysha Gene Therapies, Inc. is currently listed on NASDAQ under TSHA. One share of TSHA stock can currently be purchased for approximately $3.96. Is Taysha Gene Therapies, Inc. listed on the NASDAQ or ...